OBI Pharma Inc (台灣浩鼎) shares yesterday rose 2.29 percent following a two-day slump, after the biotech firm cleared up rumors of irregularities in the provision of stock compensation to interested parties.
Shares of OBI Pharma closed at NT$670 in Taipei trading, following declines of 2.51 percent and 6.43 percent in the past two sessions.
The company dismissed rumors that it had granted shares to Academia Sinica president Wong Chi-huey (翁啟惠), who later transferred the shares to company chairman Michael Chang (張念慈).
Academia Sinica, the nation’s leading research academy, works in close collaboration with OBI Pharma.
OBI Pharma was founded by Chang and Wong as a wholly owned subsidiary of US-based Optimer Pharmaceuticals Inc in April of 2012. Optimer Pharmaceuticals ousted Chang, who had served as chairman at OBI Pharma, on suspicion that Chang had arranged for a grant of 1.5 million OBI Pharma shares to himself for the benefit of a third party.
OBI Pharma said that throughout the company’s history, it has never approved share grants for members of its research team, management or interested parties.
In addition, the company said that Wong was not involved in Optimer Pharmaceutical’s October 2012 decision to sell the remaining stakes of its former subsidiary back to OBI Pharma shareholders and that Chang was later cleared of wrongdoing following probes by US financial regulators.
Chang had no control on prices in the selling of shares, which was initiated by Optimer to raise funds, OBI Pharma said, adding that the rumors are aimed at stirring controversy over the ownership of the company’s OBI-822 medicine, a promising active immunotherapy for metastatic breast cancer, after its share prices soared, while vowing to take legal action over unfounded rumors.
OBI Pharma last month announced that it has inked an agreement to transfer exclusive rights for Merck & Co Inc of the US to develop and commercialize the company’s narrow spectrum antibiotic Dificid in Taiwan.
Dificid has been approved by Taiwanese authorities to treat closridium difficile-related diarrhea in adults.
In related news, TaiGen Biotechnology Co (太景生技) shares yesterday gained 7.71 percent to climb to NT$37 after the company announced that its pneumonia drug Taigexyn is going through phase-three clinical trials and that a new drug application would be submitted to the Chinese Food and Drug Administration next year.
The news came after TaiGen said last week it had received approval from the Chinese agency for the phase-two clinical trial of Burixafor, an autologous hematopoietic stem-cell transplantation drug.
So far this year, TaiGen shares have dropped 4.27 percent on the Taipei Exchange, outperforming the over-the-counter benchmark index, which has dropped 6.35 percent over the same period.
STAYING AHEAD: Fitch said that TSMC remains technologically ahead of others, but Samsung is building a new chip fab, while China is investing in its domestic industry As escalating US-China tensions and COVID-19-related production disruptions force US technology supply chains to transform, Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) US$12 billion chip fabrication plant in Arizona would be key to spurring greater US production of core semiconductor components, Fitch Ratings said. “We view the US-TSMC alliance as a first step in building a more autonomous US technology supply chain, given high barriers to entry, specifically related to the significant capital and design capability required for leading-edge semiconductor manufacturing,” Fitch said in a statement on Tuesday. “By working with TSMC, US chipmakers will not face the financial burden of incremental investment
DIVERSIFICATION: Although COVID-19 would push more companies to produce in emerging markets, DBS said that it was unlikely that firms would totally leave China Geopolitical tensions and supply disruptions are expected to accelerate the migration of manufacturing out of China, as concerns about the risk of production concentrated in one country increase, S&P Global Ratings said. Although its economic expansion might be weaker than previous levels due to the accelerated relocation of manufacturing, China’s economic growth would still be stronger than that of most other economies, the ratings agency said. “While absolute growth rates will moderate, we believe China’s economic performance will continue to be a key sovereign credit support,” S&P Global Ratings credit analyst Tan Kim Eng (陳錦榮) said in a statement on Thursday. “Its growth
Taiwan’s corporate landscape has changed significantly over the past 20 years, with Hon Hai Precision Industry Co (鴻海精密) replacing Formosa Plastics Corp (台塑) as the revenue leader, while Taiwan Semiconductor Manufacturing Co. (TSMC, 台積電) has emerged as the most profitable firm, a survey of Taiwan’s 50 largest companies published on Tuesday last week showed. The Chinese-language CommonWealth Magazine survey ranked Taiwan’s 50 largest companies based on their revenue last year, and compared them with the results of a similar survey it conducted in 2000. Only 33 companies on the original list remained in this year’s rankings, the survey found, following two
GEOPOLITICAL RISKS: Beijing announced plans to strengthen ‘enforcement’ in Hong Kong, sparking losses across Asia led by the Hang Seng’s 5.6 percent plunge Local shares on Friday ended sharply lower amid renewed tensions between the US and China over Chinese telecommunications equipment giant Huawei Technologies Co Ltd (華為) and China’s plan to introduce a national security law in Hong Kong. The TAIEX on Friday finished down 197.16, or 1.79 percent, at 10,811.15 on turnover of NT$177.183 billion (US$5.9 billion), almost flat from a close of 10,814.92 on May 15. The market was down across all major sectors, in particular electronics shares, which finished down 1.99 percent from Thursday’s close. Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), the world’s largest wafer foundry and a chip supplier